INCY — Incyte
Health Care|Biotechnology
4 Articles
INCYEarningspositive
Incyte Delivers 21% Revenue Jump to $1.27B as Cancer Drug Portfolio Expands
Incyte reported Q1 2026 earnings of $1.47 per share with revenue growing 21% to $1.27 billion, driven by strong sales across its oncology portfolio and four anticipated drug approvals.
4 min read
INCYLeadershipneutral
Incyte Board Member Susanne Schaffert Resigns, Effective April 15
Dr. Susanne Schaffert notified Incyte Corporation of her resignation from the Board of Directors, effective April 15, 2026, after four years of service.
3 min read
INCYLeadershipneutral
Incyte Reshuffles Leadership, Names Pablo Cagnoni President in Strategic Reorganization
Incyte Corporation announces executive title changes with Pablo Cagnoni becoming President while CEO William Meury retains his chief executive role.
3 min read
INCYEarningspositive
Incyte Reports Record $6.41 EPS for 2025, Capping Strong Year
Incyte Corporation delivered full-year 2025 earnings of $6.41 per share on revenue of $3.39 billion, with net income reaching $1.29 billion.
3 min read